Identification

Name
Fasudil
Accession Number
DB08162
Description

Fasudil has been investigated in Carotid Stenosis.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 291.369
Monoisotopic: 291.104147493
Chemical Formula
C14H17N3O2S
Synonyms
Not Available
External IDs
  • AT 877
  • AT-877
  • HA 1077
  • HA-1077
  • ZK-258594

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UcAMP-dependent protein kinase inhibitor alphaNot AvailableHumans
UcAMP-dependent protein kinase catalytic subunit alphaNot AvailableHumans
URho-associated protein kinase 1Not AvailableHumans
URho-associated protein kinase 2Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Fasudil.
AcebutololThe risk or severity of bradycardia can be increased when Fasudil is combined with Acebutolol.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Fasudil.
AcetyldigitoxinFasudil may increase the arrhythmogenic activities of Acetyldigitoxin.
AdenosineAdenosine may increase the arrhythmogenic activities of Fasudil.
AjmalineAjmaline may increase the arrhythmogenic activities of Fasudil.
AlbiglutideThe therapeutic efficacy of Albiglutide can be increased when used in combination with Fasudil.
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Fasudil.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Fasudil.
AlogliptinThe therapeutic efficacy of Alogliptin can be increased when used in combination with Fasudil.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Fasudil hydrochlorideSQ04N8S7BR105628-07-7LFVPBERIVUNMGV-UHFFFAOYSA-N

Categories

ATC Codes
C04AX32 — Fasudil
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as isoquinolines and derivatives. These are aromatic polycyclic compounds containing an isoquinoline moiety, which consists of a benzene ring fused to a pyridine ring and forming benzo[c]pyridine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoquinolines and derivatives
Sub Class
Not Available
Direct Parent
Isoquinolines and derivatives
Alternative Parents
1,4-diazepanes / Pyridines and derivatives / Organosulfonamides / Benzenoids / Sulfonyls / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
1,4-diazepane / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Diazepane / Heteroaromatic compound / Hydrocarbon derivative / Isoquinoline / Organic nitrogen compound
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
Q0CH43PGXS
CAS number
103745-39-7
InChI Key
NGOGFTYYXHNFQH-UHFFFAOYSA-N
InChI
InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2
IUPAC Name
5-(1,4-diazepane-1-sulfonyl)isoquinoline
SMILES
O=S(=O)(N1CCCNCC1)C1=CC=CC2=C1C=CN=C2

References

General References
Not Available
PubChem Compound
3547
PubChem Substance
99444633
ChemSpider
3426
BindingDB
14027
ChEMBL
CHEMBL38380
ZINC
ZINC000000006486
PDBe Ligand
M77
Wikipedia
Fasudil
PDB Entries
1q8w / 2esm / 2f2u / 2gni / 3tku / 5lcp / 5nw8 / 5o0e / 5ok3 / 5vef
show 7 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
3CompletedTreatmentDiabetic Macular Edema (DME)1
3CompletedTreatmentRaynaud's Phenomenon / Scleroderma1
2CompletedBasic ScienceCardiovascular Heart Disease1
2CompletedTreatmentAtherosclerosis / High Cholesterol1
2RecruitingTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2TerminatedOtherCarotid Stenosis1
2Unknown StatusTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2, 3RecruitingTreatmentRetinopathy of Prematurity1
2, 3Unknown StatusTreatmentRetinal Vein Occlusion1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.531 mg/mLALOGPS
logP0.16ALOGPS
logP0.32ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)8.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area62.3 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity77.92 m3·mol-1ChemAxon
Polarizability29.6 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9614
Caco-2 permeable-0.6507
P-glycoprotein substrateSubstrate0.5902
P-glycoprotein inhibitor INon-inhibitor0.616
P-glycoprotein inhibitor IINon-inhibitor0.8386
Renal organic cation transporterNon-inhibitor0.5342
CYP450 2C9 substrateNon-substrate0.7243
CYP450 2D6 substrateNon-substrate0.7464
CYP450 3A4 substrateNon-substrate0.5632
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.7888
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.73
Ames testNon AMES toxic0.682
CarcinogenicityNon-carcinogens0.8969
BiodegradationNot ready biodegradable0.9793
Rat acute toxicity2.5211 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7322
hERG inhibition (predictor II)Inhibitor0.5551
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein kinase a catalytic subunit binding
Specific Function
Extremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulato...
Gene Name
PKIA
Uniprot ID
P61925
Uniprot Name
cAMP-dependent protein kinase inhibitor alpha
Molecular Weight
7988.435 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Phosphorylates a large number of substrates in the cytoplasm and the nucleus. Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which bin...
Gene Name
PRKACA
Uniprot ID
P17612
Uniprot Name
cAMP-dependent protein kinase catalytic subunit alpha
Molecular Weight
40589.38 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein serine/threonine kinase activity
Specific Function
Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesio...
Gene Name
ROCK1
Uniprot ID
Q13464
Uniprot Name
Rho-associated protein kinase 1
Molecular Weight
158173.545 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Structural molecule activity
Specific Function
Protein kinase which is a key regulator of actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesio...
Gene Name
ROCK2
Uniprot ID
O75116
Uniprot Name
Rho-associated protein kinase 2
Molecular Weight
160898.555 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:28 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates